暴涨6倍，股东又减持！

Core Viewpoint - The second largest shareholder of Hotgen Biotech, Zhou Xin, plans to reduce his holdings by up to 1.8 million shares due to personal financial needs, following a significant increase in the company's stock price [2][3]. Shareholder Actions - Zhou Xin intends to sell up to 1.8 million shares, representing approximately 1.94% of the total share capital of Hotgen Biotech [2]. - Based on the closing price on June 25, 2024, this sale could yield around 250 million yuan [3]. - Prior to this planned reduction, Zhou Xin had already cashed out approximately 210 million yuan from his holdings [4][6]. Historical Context - Zhou Xin held a 10.35% stake at the time of Hotgen Biotech's IPO in September 2019 and remains the second largest shareholder with 6.81 million shares, or 7.34% of the total [5]. - He previously cashed out approximately 21.59 million yuan in 2017 and 65.59 million yuan in 2018, totaling around 87.18 million yuan before the company's IPO [5]. - Since the IPO, Zhou Xin has realized approximately 123 million yuan through secondary market transactions [6]. Stock Performance - The stock price of Hotgen Biotech has experienced significant volatility, with a notable increase of over 6 times since September 2024 [7]. - The company saw a dramatic rise in stock price in April 2021, which was followed by a major sell-off by Zhou Xin in July 2021 [7]. Financial Performance - In 2024, Hotgen Biotech reported a revenue of 511 million yuan, a year-on-year decrease of 6.74%, and a net loss of 191 million yuan, representing a significant decline of 760.4% [12]. - The company's performance has been impacted by the post-COVID-19 market adjustments, leading to a substantial decline in both revenue and stock price [11]. Strategic Initiatives - Hotgen Biotech is focusing on innovative biopharmaceutical technologies through its "Future Technology Research Institute," with strategic investments in companies like Yaojing Gene and Shunjing Medicine [16]. - The company is involved in the development of cutting-edge antibody and nucleic acid drugs, including a global first heart attack emergency antibody drug and an Alzheimer's treatment antibody [17].